The response rate of HBV-associated HCC to anti PD-1/PD-L1 antibodies is less than 30% (5), indicating that blocking the PD-1/PD-L1 pathway is not effective in restoring T cell function. The gene discussed is CD274; the disease is hepatocellular carcinoma.